ArticleNature cancer2021

A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors.

Jia Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.